Australia's Therapeutic Goods Administration (TGA) has issued a warning linking GLP-1 drugs like Ozempic to a rare but severe eye disorder that can cause blindness. The regulator identified 36 cases of non-arteritic anterior ischaemic optic neuropathy (NAION) among patients using these medications, which are commonly prescribed for type 2 diabetes and obesity.
The TGA updated product information for Ozempic, Wegovy, and Mounjaro to reflect this risk. While NAION is extremely rare, the agency stresses that anyone experiencing sudden vision loss—even partial—should seek urgent medical attention.
Find Original, High-end Home Decor that spark conversation at Grand Goldman Shop.
What Is NAION and How Is It Linked to GLP-1 Drugs?
Non-arteritic anterior ischaemic optic neuropathy (NAION) occurs when blood flow to the optic nerve is interrupted, leading to permanent vision impairment. The TGA first flagged the connection in 2024 after a peer-reviewed study, and ongoing monitoring has strengthened the evidence.
Professor Helen Danesh-Meyer from the Royal Australian and New Zealand College of Ophthalmologists warns that while the condition is frightening, patients should weigh the risks against the proven benefits of these drugs in preventing heart attacks, strokes, and kidney disease.
Comparison of GLP-1 Drugs and NAION Risk
| Drug | Common Use | Reported NAION Cases (Australia) |
|---|---|---|
| Ozempic (semaglutide) | Type 2 diabetes | 18 |
| Wegovy (semaglutide) | Obesity | 10 |
| Mounjaro (tirzepatide) | Type 2 diabetes / obesity | 8 |
Note: Numbers are approximate based on TGA reports as of early 2025.
Key Takeaways for Patients
- Do not stop your medication without consulting your doctor first.
- Monitor for sudden vision changes, including partial loss of sight.
- Report any visual symptoms immediately to your healthcare provider.
- Understand that NAION is very rare—the benefits of GLP-1 drugs often outweigh the risks.
- Stay informed by reading updated product information from the TGA.
FAQs About GLP-1 Drugs and Eye Health
What is NAION?
NAION stands for non-arteritic anterior ischaemic optic neuropathy, a condition where the optic nerve loses blood supply, often leading to permanent vision loss. It has been linked to GLP-1 receptor agonists like Ozempic.
Should I stop taking Ozempic if I'm worried about blindness?
No. The TGA advises patients not to stop treatment without medical advice. The risk of NAION is extremely low, while the benefits of managing diabetes or obesity can be life-saving.
How common is NAION in people taking GLP-1 drugs?
In Australia, only 36 cases have been reported among hundreds of thousands of users. Ophthalmologists describe it as a "very rare" condition, so the absolute risk remains very small.
What symptoms should I watch for?
Sudden vision loss, blurring, or darkening in one eye—especially if it occurs without pain—requires immediate medical attention. Even partial loss of vision should be treated as an emergency.
The TGA continues to monitor the situation and will update guidance as more evidence emerges. For now, experts emphasize that the benefits of GLP-1 drugs in controlling blood sugar and weight generally outweigh the extremely low risk of this eye disorder.
Browse the Shop
Acacia frida deluxe solid wood bed frame |
Bedroom bench |
Bed chest drawers |
Lingerie dresser |
Frame base |
Mirror with jewelry storage |
30 Bathroom Vanity |
Memory foam queen mattress |
Mattresses for back pain |
Nightstand set of 2 |
Grand Goldman Shop |
Civil Lawyer
Deutschland Trikot WM 2026
